Business Context and Reporting Period
This Form 8-K is a current report filed by InMed Pharmaceuticals Inc. on July 22, 2026. The filing discloses an amendment to a pre-closing financing agreement related to the proposed merger between InMed and Mentari Therapeutics, Inc. (Mentari). The transaction involves a two-step merger where Mentari will become a wholly-owned subsidiary of InMed.
Key Financial Metrics and Transaction Details
- Financing Amount: An additional $200 million in securities (Additional Shares and/or Additional Pre-Funded Warrants) was agreed upon with Original and New Investors.
- Pricing: The purchase price for Additional Shares is 152.80% of the price paid by Original Investors. Additional Pre-Funded Warrants are priced at the Additional Share price minus $0.0001.
- Ownership Structure (Pro Forma): Upon closing, pre-Merger Mentari stockholders are expected to own approximately 98.85% of the combined company, while pre-Merger InMed shareholders will own approximately 1.15%.
- Share Count: The total common stock of the combined company on an as-converted/as-exercised basis is expected to be approximately 601,195,812 shares.
- Cash Runway: The amended financing is expected to extend Mentari's cash runway into 2029.
Material Changes and Strategic Impact
The primary material change is the execution of Amendment No. 1 to the Securities Purchase Agreement dated May 19, 2026. This amendment increases the capital raised in the Pre-Closing Financing by $200 million. The proceeds are designated to support:
- Phase 2a readouts for two PACAP-targeted lead programs, including MT-002.
- Clinical development of Mentari's broader migraine prevention pipeline.
The filing notes that proceeds from the sale of the Additional Securities are excluded from the valuation framework used to determine the Exchange Ratio under the Merger Agreement.
Outlook, Risks, and Contingencies
Outlook: Management expects the transaction to close subject to the satisfaction or waiver of conditions, including shareholder approval and regulatory approvals. The combined entity aims to advance its migraine prevention pipeline through 2029.
Risks and Contingencies: The filing highlights several risks that could prevent the transaction from closing or alter its terms:
- Failure to obtain shareholder approval.
- Failure to complete the Pre-Closing Financing.
- Delays in or adverse outcomes related to regulatory approvals.
- Potential termination of the Merger Agreement.
- Unexpected costs or the inability to maintain Nasdaq listing.
Unusual Items: The filing contains forward-looking statements regarding the structure, timing, and completion of the merger and financing, which are subject to significant uncertainties.
Investor Verification Checklist
- Verify the final terms of the Amendment No. 1 filed as Exhibit 10.1.
- Confirm the status of shareholder approval for the merger and the financing.
- Review the Form S-4 (filed July 2, 2026) for the complete proxy statement/prospectus and detailed risk factors.
- Monitor regulatory approval status for the proposed merger.
- Assess the impact of the 1.15% ownership stake remaining for existing InMed shareholders post-merger.